Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1955 3
1958 1
1959 1
1961 3
1962 2
1963 2
1964 5
1965 1
1966 4
1967 10
1968 6
1969 9
1970 5
1971 15
1972 16
1973 17
1974 16
1975 8
1976 14
1977 21
1978 11
1979 33
1980 16
1981 25
1982 8
1983 26
1984 32
1985 33
1986 31
1987 20
1988 23
1989 47
1990 30
1991 40
1992 41
1993 37
1994 47
1995 43
1996 58
1997 55
1998 60
1999 68
2000 75
2001 85
2002 107
2003 101
2004 119
2005 143
2006 137
2007 153
2008 156
2009 149
2010 161
2011 168
2012 223
2013 216
2014 251
2015 272
2016 233
2017 281
2018 286
2019 280
2020 317
2021 343
2022 290
2023 304
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

5,331 results

Results by year

Filters applied: . Clear all
Page 1
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, McKiernan J, Anderson CB, Decastro GJ, Weintraub J, Virk R, Lowy I, Hu J, Chaimowitz MG, Guo XV, Zhang Y, Haffner MC, Worley J, Stein MN, Califano A, Drake CG. Hawley JE, et al. Cancer Cell. 2023 Nov 13;41(11):1972-1988.e5. doi: 10.1016/j.ccell.2023.10.006. Epub 2023 Nov 2. Cancer Cell. 2023. PMID: 37922910 Free article.
When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRPC) is relatively devoid of immune infiltrates. While androgen deprivation therapy (ADT) induces a complex immune infiltrate in localized pro …
When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRPC) is relative …
Should Dehydroepiandrosterone Be Administered to Women?
Wierman ME, Kiseljak-Vassiliades K. Wierman ME, et al. J Clin Endocrinol Metab. 2022 May 17;107(6):1679-1685. doi: 10.1210/clinem/dgac130. J Clin Endocrinol Metab. 2022. PMID: 35254428 Free PMC article. Review.
EVIDENCE ACQUISITION: A review of the literature from 1985 to 2021 on the potential benefits and risks of androgen prohormones in women. EVIDENCE SYNTHESIS: Studies have examined the potential benefit of DHEA therapy for anti-aging, sexual dysfunction, infert …
EVIDENCE ACQUISITION: A review of the literature from 1985 to 2021 on the potential benefits and risks of androgen prohormones in wom …
Acne fulminans.
Dall'oglio F, Puglisi DF, Nasca MR, Micali G. Dall'oglio F, et al. G Ital Dermatol Venereol. 2020 Dec;155(6):711-718. doi: 10.23736/S0392-0488.20.06711-5. Epub 2020 Oct 21. G Ital Dermatol Venereol. 2020. PMID: 33084268 Free article. Review.
Dapsone, cyclosporine A, methotrexate, azathioprine, levamisole, and biological agents such as anakinra, infliximab, adalimumab may be considered as alternative therapies in selected cases. Adjunctive topical and physical therapies may also be considered....
Dapsone, cyclosporine A, methotrexate, azathioprine, levamisole, and biological agents such as anakinra, infliximab, adalimumab may be consi …
Anti-androgen hormonal therapy for cancer and other diseases.
Student S, Hejmo T, Poterała-Hejmo A, Leśniak A, Bułdak R. Student S, et al. Eur J Pharmacol. 2020 Jan 5;866:172783. doi: 10.1016/j.ejphar.2019.172783. Epub 2019 Nov 8. Eur J Pharmacol. 2020. PMID: 31712062 Free article. Review.
As a result of increased knowledge of the role of androgens in different diseases, anti-androgen treatment is becoming increasingly important in targeted therapy. ...Herein, we review anti-androgen therapies in cancer and other sel …
As a result of increased knowledge of the role of androgens in different diseases, anti-androgen treatment is becoming …
Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation.
Yang L, Zhou R, Tong Y, Chen P, Shen Y, Miao S, Liu X. Yang L, et al. Neurobiol Dis. 2020 Jul;140:104814. doi: 10.1016/j.nbd.2020.104814. Epub 2020 Feb 19. Neurobiol Dis. 2020. PMID: 32087283 Free article.
Microglia-induced neuroinflammation plays a vital role in the etiology and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and multiple sclerosis. The neuroprotective role of androgens, including testosterone and its metabolite …
Microglia-induced neuroinflammation plays a vital role in the etiology and progression of neurodegenerative diseases, including Alzheimer's …
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA, Yen AE, Weigel NL. Shafi AA, et al. Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Pharmacol Ther. 2013. PMID: 23859952 Review.
Androgen action is mediated by the androgen receptor (AR), a hormone activated transcription factor. The primary treatment for metastatic PCa is androgen deprivation therapy (ADT). For the most part, tumors respond to ADT, but most become resistant to …
Androgen action is mediated by the androgen receptor (AR), a hormone activated transcription factor. The primary treatment for …
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). Goodman NF, et al. Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC. Endocr Pract. 2015. PMID: 26509855
Physiologic doses of dexamethasone or prednisone can directly lower adrenal androgen output. Anti-androgens can be used to block the effects of androgen in the pilosebaceous unit or in the hair follicle. ...Anti-androgen therapy in …
Physiologic doses of dexamethasone or prednisone can directly lower adrenal androgen output. Anti-androgens can be used …
Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality - a preliminary study.
Fuchs A, Matonóg A, Sieradzka P, Pilarska J, Hauzer A, Czech I, Drosdzol-Cop A. Fuchs A, et al. Ginekol Pol. 2019;90(9):520-526. doi: 10.5603/GP.2019.0091. Ginekol Pol. 2019. PMID: 31588549 Free article.
OBJECTIVES: Using anti-androgenic contraception is one of the methods of birth control. ...These drugs can be used in various endocrinological disorders, because of their abilityto reduce the level of male hormones.The aim of our study is to establish a correlation …
OBJECTIVES: Using anti-androgenic contraception is one of the methods of birth control. ...These drugs can be used in various …
Spironolactone in dermatology.
Aguilar Medina DA, Cazarín J, Magaña M. Aguilar Medina DA, et al. Dermatol Ther. 2022 May;35(5):e15321. doi: 10.1111/dth.15321. Epub 2022 Mar 17. Dermatol Ther. 2022. PMID: 35038224 Review.
Spironolactone is a drug, similar in structure to aldosterone and acts as an aldosterone receptor antagonist with an anti-androgenic effect. This drug has proven to be useful in several dermatological entities, however its use has not been well explored. Its use in …
Spironolactone is a drug, similar in structure to aldosterone and acts as an aldosterone receptor antagonist with an anti-androgen …
Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Militaru FC, Militaru V, Crisan N, Bocsan IC, Udrea AA, Catana A, Kutasi E, Militaru MS. Militaru FC, et al. Biomol Biomed. 2023 Sep 4;23(5):760-771. doi: 10.17305/bb.2023.8782. Biomol Biomed. 2023. PMID: 37021836 Free PMC article. Review.
Most prostate cancers can be treated by targeting the androgen-receptor pathway and decreasing androgen production or binding to androgen receptors (AR). ...Most benefits were demonstrated in cyclin dependent-kinase 12 (CDK12) mutated cell lines when treated …
Most prostate cancers can be treated by targeting the androgen-receptor pathway and decreasing androgen production or binding …
5,331 results